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Myeloid-derived suppressor cells (MDSCs) are regulatory cell populations that have the ability to suppress
effector T cell responses and promote the development of regulatory T cells (Tregs). They are a heterogeneous
population of immature myeloid progenitors that include monocytic and granulocytic subsets. We postulated
that given the rapid expansion of myeloid cells post-transplant, these members of the innate immune system
may be important contributors to the early immune environment post-transplant. To evaluate the kinetics of
recovery and function of MDSCs after allogeneic hematopoietic stem cell transplant (HSCT), 26 patients
undergoing allogeneic HSCT were studied at 6 time points in the ﬁrst 3 months after HSCT. Both MDSC
subsets recovered between 2 and 4 weeks, well before the recovery of T and B lymphocytes. MDSC subset
recovery positively correlated with T, B, and/or double-negative T cell numbers after HSCT. MDSCs isolated
from patients post-transplant were functional in that they suppressed third-party CD4þ T cell proliferation
and Th1 differentiation and promoted Treg development. In conclusion, functional MDSC are present early
after HSCT and likely contribute to the regulatory cell population post-transplant.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) involves rapid expansion of the hematopoietic
compartment after infusion of hematopoietic stem cell con-
taining products that have been either harvested from
marrow/cord blood or collected by growth factor mobiliza-
tion. All populations contain large numbers of immature
myeloid cells that contain a potent immune regulatory pop-
ulation known as myeloid-derived suppressor cells (MDSCs).
MDSCs are a heterogeneous population of activated
immature myeloid progenitor cells; precursors to macro-
phages, granulocytes, and dendritic cells that have been pre-
vented from fully differentiating into mature cells [1,2].
MDSCs are potent suppressors of T cells through direct celldgments on page 1213.
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ty for Blood and Marrow Transplantation.contact, increased production of arginase 1 (Arg-1), inducible
nitric oxide synthase (iNOS), indoleamine 2,3-dioxygenase
(IDO) and reactive oxygen species, and induction of regula-
tory T cells (Tregs) [1,2].
The expansion and functional importance of MDSCs in
cancer and noncancer pathogenic conditions has been
recognized. MDSC numbers are increased, and they act as
immune regulatory cells in autoimmune diseases [3], solid
organ transplantation [4,5], and allergic asthma [6]. We have
reported that the numbers ofMDSCs are positively correlated
with the severity of murine colitis and that adoptive transfer
of MDSCs isolated from murine colitis models or generated
in vitro ameliorate murine intestinal inﬂammation [7].
Allogeneic HSCT transplantation is associated with a
massive expansion of myeloid cell compartment, both in the
donor with granulocyte colony-stimulating factor (G-CSF)
mobilized hematopoietic stem cell collection and in the
recipient early post-transplant. Both G-CSF and granulocyte-
macrophage (GM)-CSF have been shown to expand MDSCs
[8]. Cytokines prominent in the early post-transplant period,
Table 1
Patient Demographics and Transplant Outcomes (N ¼ 26)
Characteristic Value
Sex (female/male) 8/18
Disease
Acute myelogenous leukemia 11
Non-Hodgkin lymphoma 4
Myelodysplastic/ﬁbrotic syndrome 4
Acute lymphoblastic leukemia 3
Chronic lymphocytic leukemia 1
Severe aplastic anemia/Fanconi anemia 2
Common variable immunodeﬁciency 1
Median age at transplant, yr (range) 43 (13-62)
Donor source
G-CSF mobilized PBSCs (16 unrelated, 6 related) 22
Bone marrow (2 unrelated, 1 related) 3
Cord blood (1 unrelated) 1
Conditioning regimen
Myeloablative 13
Nonmyeloablative 13
Acute GVHD
None or GVHD grade I 13
GVHD grades II-IV 13
Median days to achieve ANC 500/mL (range) 18 (12-28)
Median days of platelet recovery to
20  109/L* (range)
21 (13-47)
Median CD34þ stem cells transplanted,
106/kg (range)
PBSCs 5.4 (2.0-8.0)
Bone marrow 2.7 (1.5-3.8)
Cord blood .21
PBSC indicates peripheral blood stem cell; ANC, absolute neutrophil count.
* Six patients did not have a nadir of platelets below 20  109/L.
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known to activate or license MDSCs to become potent sup-
pressors of multiple aspects of the immune system [9]. Small
series have suggested that MDSCs are present in the grafts
and recipients early after HSCT [10-12].
MDSC are divided into 2 main subsets, monocytic
(M-MDSC) and granulocytic (G-MDSC), based on expression
of monocytic or granulocytic cell surface markers [1,9]. Each
subset may have different functions under varying inﬂam-
matory conditions. In a murine asthma model, M-MDSC
inhibited whereas G-MDSC exacerbated airway inﬂamma-
tion [6]. Furthermore, timing appears to be important. In a
sepsis model, MDSCs exaggerated inﬂammation in the early
stage but suppressed inﬂammation in the later stage of
sepsis [13].
In murine GVHD transplant models, MDSC accumulation
in recipient mice post-transplantation was positively corre-
lated with the severity of graft-versus-host disease (GVHD)
[14]. The infusion of embryonic stem celle or bone mar-
rowederived MDSCs before transplantation provided pro-
tection from lethal acute GVHD, leading to long-term
survival in 37% [15] or 82% [16] of recipient mice. Adoptive
transfer of MDSCs preserved graft-versus-leukemic (GVL)
effects of allogeneic host T cells in a GVL model [15]. Mou-
giakakos et al. [10] found that CD14þHLA-DR/lowIDOþ
monocytic MDSCs in peripheral blood mononuclear cells
(PBMCs) are signiﬁcantly increased in patients with acute
GVHD and that these MDSCs could suppress the proliferation
of lymphocytes through IDO in vitro. More recently, another
study showed extracorporeal photopheresis treatment in
patients with GVHD rapidly increased the percentage of
circulating G-MDSCs in PBMCs, which efﬁciently suppressed
effector CD4 T cell responses [17]. G-MDSCs may be under-
appreciated in previous studies of leukocytes post-transplant
because they sediment with red blood cells in conventional
density gradient cell preparations (eg, Ficol) and do not
survive freezeethaw well.
To date, reconstitution of MDSC subsets after allogeneic
HSCT and the relation of MDSC subsets to acute GVHD have
not been well deﬁned. We were interested in understanding
the kinetics of MDSC recovery post-HSCT, their functionality,
and whether they were associated with acute GVHD.METHODS
Patients
Patients undergoing allogeneic HSCT were enrolled on a trial evaluating
early immune recovery after allogeneic HSCT. This study was approved by
the ethics committee of the University of Manitoba. All patients and/or their
parents signed informed consent. Patient demographics and transplant
outcomes are presented in Table 1.
There was an equal representation of myeloablative (busulfan/ﬂudar-
abine or total body irradiation based) and nonmyeloablative conditioning
regimens. Aplastic anemia patients received ﬂudarabine/cyclophosphamide
with adjusted cyclophosphamide dosing for the patient with Fanconi ane-
mia. GVHD prophylaxis was tacrolimus and mini-methotrexate (5 mg/m2 on
days þ1, þ3, and þ6, with an additional dose on day þ11 for unrelated
donors). Antithymocyte globulin was used in the aplastic anemia patients
and if there was less than 10/10 HLA match. Most patients received G-CSF
(ﬁlgrastim)emobilized grafts from family or unrelated donors with a target
cell dose of 5106 CD34 cells/kg. Filgrastim (5 mg/kg/day) was administered
daily starting on dayþ1 in the cord blood recipient until neutrophil recovery
above 1.5  109/L but was otherwise not used in the other subjects unless
there was delayed count recovery.
All recipients had documentation of donor engraftment. Neutrophil
engraftment day was deﬁned as the ﬁrst day of 3 consecutive days with
absolute neutrophil count greater than .5  109/L. Platelet engraftment day
was deﬁned as the ﬁrst of 7 consecutive days with platelet count greater
than 20  109/L without transfusion support for at least 7 days. Acute GVHD
was graded according to the modiﬁed Glucksberg criteria [18]. In the ﬁrst100 days post-transplant, 2 patients died (primary disease) and 6 patients
had progression or relapse of malignancy.
Isolation of WBCs
Twenty-four milliliters of peripheral blood was drawn on the day before
the start of the conditioning regimen, with 1 additional sample drawn each
between days þ4 and þ5, þ7 to þ9, þ14 to þ16, þ21 to þ23, þ27 to þ29,
and þ80 to þ100 after HSCT, for a total of 7 samples per subject. WBCs were
isolated from peripheral blood using HetaSep (Stem Cell Technologies,
Vancouver, Canada) according to the manufacturer protocol. All blood
samples were processed and analyzed 24 hours after drawing.
Antibodies and Flow Cytometry
WBCswere stainedwith ﬂuorescence-labeled antibodies against surface
molecules for MDSC subsets (HLA-DR, CD45, CD33, CD15, CD66b, and CD14),
B cells (CD19), and T cells (CD3, CD4, and CD8) (eBioscience, San Diego, CA;
Biolegend, San Diego, CA) according to manufacturer recommendations.
After staining, cells were acquired and analyzed using ﬂow cytometry (FACS
Canto II; BD Biosciences, San Jose, CA) and FlowJo software (TreeStar, San
Carlos, CA) [10,17]. For intracellular staining of Arg-1 and iNOS, cells were
ﬁrst stained with ﬂuorescence-labeled antibodies against HLA-DR, CD33,
CD15, and CD14 and then ﬁxed and permeabilized using eBioscience
intracellular ﬁxation/permeabilization buffer. Cells were then stained with
Percp-Cy5.5elabeled anti-iNOS (Santa Cruz Biotechnology, Dallas, TX) and
PE-labeled antieArg-1 (R&D systems, Minneapolis, MN), and analyzed by
ﬂow cytometry (FACS Canto II). The FACS Canto II was maintained by daily
running BD 7-color microbeads to ensure the accuracy and consistency of
the subpopulation analysis. Single staining tubes and isotype control
staining tubes were used to do the compensation for all runs.
T Cell Proliferation and Differentiation Assay
To evaluate the function of the MDSC subsets, M-MDSCs and G-MDSCs
were enriched by positive selection from the peripheral blood using CD14þ
selection kit and CD15þ selection kit (StemCell Technologies) according to the
manufacturer protocol. The purity of M-MDSC and G-MDSC cells was
conﬁrmed by ﬂow cytometry. The control population was CD14CD15 cells
that contained all lymphocytes. The suppressive effect of MDSC subsets on
lymphocyte proliferation and Tcell differentiationwas evaluated as described
previously [10]. Brieﬂy, third-party PBMCs were isolated from healthy donors
and labeled with carboxyﬂuorescein succinimidyl ester (CFSE). The 1  105
CFSE-labeled PBMCs were then stimulated with anti-CD3/CD28 microbeads
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G-MDSCs, or control cells at the ratios of PBMC/MDSC/control cells (1:1 and
1:.5) in 96-well plates for 5 days. Cells were then stained with ﬂuorescence-
labeled antibodies against CD4 and IFN-g for detecting CD4þ T cell prolifer-
ation and Th1 differentiation. To evaluate the effects of MDSC subsets on the
differentiation of Tregs, 1  105 CFSE-labeled PBMCs were stimulated with
anti-CD3/CD28 microbeads (1.8 mL/well) in the presence of recombinant
human transforming growth factor-b (5 ng/mL; Peprotech, Rocky Hill, NJ) for
5 days. Stimulator cells were added into the culture at the beginning. After 5
days, cells were stained with ﬂuorescence-labeled antibodies against CD4,
CD25, and Foxp3 to detect Tregs. Cells were analyzed by ﬂow cytometry.
Statistical Analysis
Values were expressed as means  standard deviation when normally
distributed and with boxplots when not normally distributed.Figure 1. Gating strategy of MDSC subsets. (A) CD45þ cells; (B) CD33þ cells; (C) CD15
cells, G-MDSCs.Mann-Whitney tests were used to compare MDSC subset values between
GVHD groups. ANOVA followed by the Newman-Keuls multiple compari-
son test was used to compare production of mediators in MDSC subsets.
Spearman correlations were used to assess the relationship between cell
values. All statistical analyses were performed using GraphPad Prism,
version 5 (GraphPad Prism, La Jolla, CA). P < .05 was considered to be
statistically signiﬁcant.RESULTS
MDSC Subsets Recover Early in Patients after Allo-HSCT
Several markers have been used to deﬁne human MDSCs
and subsets. Commonly used for human MDSC characteriza-
tions are CD33, CD11b, CD14, HLA-DR, CD15, or CD66b, and, in cells and CD15þ cells; (D) CD14þHLA-DR/low cells, M-MDSCs; and (E) CD66þ
Q. Guan et al. / Biol Blood Marrow Transplant 21 (2015) 1205e12141208some cases, lineage negative [19-21]. We used
CD33þCD14þHLA-DR/low to deﬁne M-MDSCs and
CD33þCD15þCD66bþ to deﬁne G-MDSCs (Figure 1). As ex-
pected, the total WBC count fell immediately post-HSCT due
to the conditioning regimen and recovered over the next 3
weeks (Figure 2A). The median number of days to neutrophil
and platelet recovery was 18 and 21 days, respectively
(Table 1). Themedian percentage ofM-MDSCs fell from 1.44%
(interquartile range [IQR], .45% to 3.19%) at the pre-
conditioning samples to .06% (IQR, .01% to .09%) at days 4 and
5 post-transplant and then recovered to 3.93% (IQR, 1.53% to
10.02%) of total WBCs at days 14 to 16 post-transplant
(Figure 2B). This translated into the median number ofFigure 2. Time course of recovery of MDSC subsets in patients after allo-HSCT. WBCs w
cytometry. The recovery of WBCs (A), percentage (B) and number (C) of M-MDSCs, an
IQRs of 12 healthy donors.M-MDSCs dropping from 5.2104/mL (IQR, 2.14 to 9.9 104/
mL) at the preconditioning samples to .02  104/mL (IQR, .01
to .16  104/mL) at days 4 to -5 post-transplant and then
recovered to 5.9 104/mL (IQR, .46 to 15.21104/mL) at days
14 to 16 post-transplant (Figure 2C). Recovery of G-MDSCs
similarly occurred early post-transplant but appeared slightly
more delayed compared with M-MDSCs (Figure 2D,E). Me-
dian G-MDSC numbers remained below normal ranges until
daysþ21 toþ23,with recovery tonormal ranges occurring by
days þ27 to þ29 post-transplant. Despite some patients still
being leukopenic early post-transplant, over 60% of patients
had MDSC subset levels in the normal range at these early
post-transplant time points.ere isolated, and the phenotype of MDSC subsets were analyzed through ﬂow
d percentage (D) and number (E) of G-MDSCs. Shaded area is the median with
Figure 3. Recovery of MDSC subsets in patients accepting myeloablative (MA) or nonmyeloablative (NMA) chemotherapy regimens. (A) M-MDSC recovery in patients
receiving NMA, (B) G-MDSC recovery in patients receiving NMA, (C) M-MDSC recovery in patients receiving MA, and (D) G-MDSC recovery in patients receiving MA.
Shaded area is the median with IQRs of 12 healthy donors.
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G-MDSCs was observed with type of conditioning regimen.
In both myeloablative and nonmyeloablative conditioning
regimens, median M-MDSC numbers were in the normal
range by days þ14 to þ16 (Figure 3A,C) and G-MDSC
numbers by days þ27 to þ29 (Figure 3B,D).
The recovery of adaptive immune CD19þ B lymphocytes
and CD3þ T lymphocytes were also evaluated. Neither B
lymphocyte nor T lymphocyte numbers recovered in the ﬁrst
100 days after allo-HSCT (Figure 4A,B), consistent with pre-
vious reports [22,23]. Double-negative (DN) T cells, deﬁned
as CD3þCD4CD8, exist as a small population of T lym-
phocytes in peripheral blood and lymphoid organs [24]. DN T
cells have shown to be capable of controlling GVHD [24]. As
shown in Figure 4C, the median number of DN T cell
decreased from 3.19  104/mL (IQR, .83 to 5.63  104/mL) at
the precondition to .26  104/mL (IQR, .10 to .84  104/mL) at
days 7 to 9 post-transplant and then recovered to 2.20 104/
mL (IQR, .48 to 5.68  104/mL) at days 27 to 29 post-
transplant. Taken together, our results indicated that im-
mune recovery of both M- and G-MDSC subsets was much
more rapid than recovery of CD19þ B and CD3þ T cells.
Relationship of MDSC Subsets with Other Immune Cells
Because MDSC subsets can modulate the functions of
other immune cells, such as T cells and Tregs, we wanted to
evaluate the relationships between the immune reconstitu-
tion of MDSC subsets with other immune cells, in particular
whether the speed of MDSC recovery in individual patientswas associated with T cell or B cell recovery. First, the
number of MDSC subsets at different time points post-
transplantation was evaluated for correlation with other
immune cells using the Spearman test. As shown in Table 2,
M-MDSC recovery positively correlated with G-MDSC re-
covery at days 14 to 16 and days 80 to 100 post-HSCT and
positively correlated with CD19þ B cell recovery at days 21 to
23. G-MDSC recovery positively correlated with CD19þ B cell
recovery at days 14 to 16, days 21 to 23, and days 80 to 100
post-HSCT; positively correlated with CD3þ T cells at days 14
to 16, days 21 to 23, and days 27 to 29 post-HSCT; and
positively correlated with DN Tcells at days 14 to 16 and days
21 to 23 post-HSCT. We then analyzed whether MDSC re-
covery in individual patients can speed up the recovery of T
and B cell recovery. There was no trend of MDSC recovery
with the speed of recovery of T and B cells in our study, but
we did not evaluate later time pointsmore relevant toTand B
cell recovery post-transplant.
Relationship of MDSC Subsets with Acute GVHD
Of 26 subjects in this study, 13 developed higher grade
acute GVHD (grades II to IV) and 13 had no or lower grade
acute GVHD (grades 0 to I). MDSC subsets were compared at
various time points between these 2 patient groups. As
shown in Figure 5A, patients who later developed higher
grade acute GVHD had higher numbers of G-MDSCs before
the start of conditioning compared with those without or
lower grade acute GVHD. At other time points, M-MDSC re-
covery or G-MDSC recovery was not associated with GVHD.
Figure 4. Time course of recovery of T lymphocytes, B lymphocytes, and DN T cells in patients after allo-HSCT. WBCs were stained with ﬂuorescence-labeled an-
tibodies against CD3 and CD19 for T and B lymphocytes and for CD3, CD4, and CD8 for DN T cells and then analyzed by ﬂow cytometry. (A) Recovery of T lymphocytes,
(B) recovery of B lymphocytes, and (C) recovery of DN T cells. Shaded area is the median with IQRs of 12 healthy donors.
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patients had lower percentages of M-MDSCs at day þ15 but
higher percentages of M-MDSCs at day þ30 compared with
Table 2
Relationship of MDSC Subsets with Other Immune Cells
M-MDSCs G-MDSCs
R P R P
Days 14-16
M-MDSCs .667 <.001
G-MDSCs .667 <.001
CD19þ B cells .212 .340 .676 <.001
CD3þ T cells .321 .146 .715 <.001
CD3þCD4CD8 DN Tregs .464 .026 .795 <.001
Days 21-23
M-MDSCs .210 .304
G-MDSCs .210 .304
CD19þ B cells .604 .001 .551 .004
CD3þ T cells .134 .514 .447 .022
CD3þCD4CD8 DN Tregs .354 .076 .422 .032
Days 27-29
M-MDSCs .119 .564
G-MDSCs .119 .564
CD19þ B cells .273 .187 .246 .236
CD3þ T cells .101 .632 .468 .018
CD3þCD4CD8 DN Tregs .005 .980 .389 .050
Days 80-100
M-MDSCs .464 .022
G-MDSCs .464 .022
CD19þ B cells .108 .625 .421 .045
CD3þ T cells .297 .158 .265 .210
CD3þCD4CD8 DN Tregs .237 .264 .185 .386
R indicates correlation coefﬁcient.nonacute GVHD patients [25]. Interestingly, in the present
study, where G-MDSC number recovered to normal range at
days 27 to 29, the ratio of G-MDSC at days 27 to 29-to-G-
MDSC at preconditioning baseline (G-MDSCR) might corre-
late with the incidence of GVHD (Figure 5B). In patients who
developed acute GVHD (grades II to IV), the median
G-MDSCR was .498 (IQR, .263 to 1.791), whereas those with
no or lower grade acute GVHD, the G-MDSCR was 2.335 (IQR,
1.409 to 6.050) (Figure 5B). Our results suggest G-MDSC
subsets before the start of conditioning or G-MDSCR may be
associated with the later development of acute GVHD, but
this needs to be conﬁrmed in a larger independent cohort.Effects of MDSC Subsets on T Cell Responses
Next, we asked whether the MDSC in patients early post-
HSCT were functional; speciﬁcally, whether they could
modulate the function of third-party T cells. MDSC subsets
were isolated from patients at days 80 to 100 post-
transplant. Our results showed that both M-MDSCs and
G-MDSCs suppressed proliferation of third-party CD4þ T
cells in a dose-dependent manner, with G-MDSCs being
more potent inhibitors of T cell proliferation (Figure 6A,B). To
evaluate the effect of MDSC subsets on the development of
Th1 and Tregs, we measured expression of CD4þIFN-gþTh1
and expansion of CD4þCD25þFoxp3þ Tregs in the coculture
system of anti-CD3/CD28 stimulated third-party lympho-
cytes. Both M-MDSCs and G-MDSCs suppressed the differ-
entiation of Th1 (Figure 6C,D) and promoted the
Figure 5. Relationship of G-MDSCs with grades II to IV acute GVHD. (A) G-MDSC numbers at preconditioning between patients who developed high grade acute
GVHD later and patients who developed low grade GVHD or without GVHD. (B) Ratio of G-MDSC number at days 27 to 29 over the baseline at the preconditioning. *P
< .05.
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control cell group.
Production of Soluble Mediators of Arg-1 and iNOS in
MDSC Subsets
MDSCs suppress effector T cell responses by multiple
mechanisms [1], 2 of which occur through Arg-1 and iNOS.
We evaluated the Arg-1 and iNOS activity in MDSC subsets in
patients pre- and post-transplant. G-MDSCs, but not M-
MDSCs, expressed signiﬁcantly higher levels of Arg-1 and
iNOS comparedwith healthy donors, both at preconditioning
and multiple time points post-transplant (Figure 7A,B).
Levels of Arg-1 or iNOS expressed in G-MDSCs in the pre-
conditioning samples were around 5 and 2 times higher than
those in healthy donors, respectively, suggesting these MDSC
subsets were activated/licensed before transplant. G-MDSCs
showed temporal down-regulation of the expression of Arg-
1 and iNOS at daysþ14 toþ16 after HSCT, but both recovered
by days þ27 to þ29 to high levels, which remained so until
days þ80 to þ100 post-HSCT. Interestingly, there was no
difference in the expression levels of Arg-1 and iNOS in
M-MDSCs among healthy donors and patients (Figure 7A,B).
DISCUSSION
The aim of this study was to analyze the kinetics of im-
mune reconstitution (both numerical and functional) of
MDSC subsets in patients undergoing allogeneic HSCT. In the
present study, we reported the early recovery of both
M-MDSC and G-MDSC subsets post-HSCT, well before the
recovery of adaptive immune CD3þ T and CD19þ B cells. We
also demonstrated both MDSC subsets were functional,
which can regulate T cell responses. The present study
especially highlighted the possible important roles of
G-MDSCs in allogeneic HSCT: G-MDSCs had stronger sup-
pressive function on lymphocyte proliferation than
M-MDSCs, the percentage and number of G-MDSCs were
signiﬁcantly higher than those of M-MDSCs, G-MDSCs
showed stronger positive correlation with other immune
cells, and G-MDSCs may predict the development of acute
GVHD. Most studies of immune recovery post-transplant
used frozen cells isolated using density gradients such as
Ficoll. Different from M-MDSCs, G-MDSCs do not survive
freezeethaw well and will sediment with RBCs in most
density gradient separations. This needs to be considered in
future studies evaluating early regulatory networks in
transplant and other settings.
The early post-transplant period is characterized by the
rapid expansion of myeloid cells [22,23]. After successfulallogeneic HSCT, monocytes are the ﬁrst cells to recover,
followed soon thereafter by granulocytes, platelets, and
natural killer cells. Expansion of lymphocytes, correlating to
cognate immune reconstitution, does not occur to any great
extent until after 100 days post-HSCT [22,23]. In the present
study, we demonstrate that both M-MDSCs and G-MDSCs
recover in the ﬁrst month post-HSCT, with M-MDSCs
recovering 1 to 2weeks earlier than G-MDSCs (Figure 1). This
is consistent with the knowledge that monocytes recover
earlier than granulocytes in patients post-HSCT. Recovery of
both MDSC subsets appears to be similar regardless of
whether a myeloablative or nonmyeloablative conditioning
regimen is used (Figure 3). Both MDSC subsets recover with
the same tempo post-HSCT (Table 2). Our results showed
that both MDSC subsets isolated from patients post-
transplant can suppress T lymphocyte proliferation, inhibit
CD4þ Th1 differentiation, but promote the development of
Tregs. All this suggests that functional MDSCs appear early
post-HSCT, and these cells could play a role in later modu-
lating T cell responses that lead to both GVHD and GVL.
Although Mougiakakos et al. [10] reported that M-MDSCs
are signiﬁcantly increased in PBMCs of patients with acute
GVHD, we could not conﬁrm this using our patient popula-
tion. Both studies may be limited by small patient numbers.
Interestingly, our results show that the ratio of G-MDSCs at
days 27 to 29 over baseline before the start of conditioning is
signiﬁcantly higher in patients who develop no or grade I
acute GVHD compared with patients who developed higher
grade acute GVHD. This suggests that rapid recovery of G-
MDSCs or even higher G-MDSCs at days 27 to 29 in patients
after allogeneic HSCT may result in a lower risk to develop
acute GVHD. We found that patients who later went on to
develop higher grades (II to IV) of acute GVHD had more
pretransplant circulating G-MDSCs (Figure 5). This is difﬁcult
to explain, given the assumption that most MDSCs would be
destroyed by the conditioning regimen. One explanation
might be that MDSCs present before the start of conditioning
are licensed and secrete large amounts of soluble inhibitors,
such as Arg-1, iNOS, and IDO, during the cell death process.
This could impact the function of alloreactive T cells in the
graft that are important in the initiation of GVHD. Our results
show that G-MDSCs expressed higher levels of Arg-1 and
iNOS in patients at preconditioning compared with those in
healthy donors. We also found that the M-MDSC subset in
both patients and healthy donors expressed dramatically
lower levels of Arg-1 and iNOS than G-MDSCs. This is
different from murine MDSCs because Arg-1 and iNOS are
thought to be the markers for M-MDSCs in mice [1]. Recent
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=Figure 7. Expression of Arg-1 and iNOS in MDSC subsets of patients after allo-HSCT. The expression of Arg-1 and iNOS in MDSC subsets were detected by intracellular
staining of Arg-1 and iNOS and analyzed by ﬂow cytometry. (A) Expression levels of Arg-1 in MDSC subsets. (B) Expression levels of iNOS in MDSC subsets. *P < .05,
**P < .01, ***P < .001.
Q. Guan et al. / Biol Blood Marrow Transplant 21 (2015) 1205e1214 1213studies showed that the suppressive function of G-MDSCs in
patients with GVHD is partially dependent on the activity of
Arg-1 [17], whereas the suppressive function of M-MDSCs in
patients post-HSCT is partially dependent on IDO [10]. A
large clinical trial is ongoing to conﬁrm this observation in
which we will study both the function of MDSCs in patients
before conditioning and evaluate the soluble mediator
expression pattern and possible roles by theseMDSCs at later
time points post-transplant.
The expansion and activation of MDSCs usually requires 2
signals. The ﬁrst signal provided by growth factors such as G-
CSF and GM-CSF promotes the differentiation and expansion
of MDSCs from myeloid progenitors [2,9]. The second signal,
provided by proinﬂammatory cytokines such as IFN-g, IL-6,
and TNF-a, leads to activation or licensing of their immune
regulatory function, including up-regulation of soluble me-
diators, such as Arg-1 and iNOS [2,9]. In the presence of GM-
CSF with TNF-a, IL-1b, or IL-6, PBMCs from healthy donors
can be converted into CD33þ MDSC-like cells [26]. The
combination of GM-CSF and IL-6 or GM-CSF and G-CSF can
also induce the differentiation and activation of MDSC from
bone marrow cells in human and mice [8].
Interestingly, these growth factors and proinﬂammatory
cytokines, which can induce the differentiation and activate
MDSCs, have also been found to be important in the patho-
genesis of GVHD [27,28]. Serum levels of IFN-g, TNF-a, and IL-
6 are increased in the ﬁrst 2 to 3 weeks after allo-HSCT
[28,29], and G-CSF was also increased in patients post-
transplantation [10]. Our data show that both MDSC sub-
sets recovered within 1 month post-transplantation. We
hypothesize that the early post-transplant immune envi-
ronment has the required elements to expand and activate
MDSCs and that MDSC recovery and function in patients
post-transplant is dependent on the growth factor and
proinﬂammatory cytokines milieu post-transplant.
One study has indicated that the percentage of M-MDSCs
is correlated with the serum levels of G-CSF, IL-6, and IL-10
in patients after allo-HSCT [10]. Clinically, growth factors
are variably used post-transplant to speed neutrophil re-
covery. MDSCs induced by different growth factors and/or
cytokines may have different suppressive functions [8].
Therefore, differences in clinical practice with respect toFigure 6. Function assay of MDSC subsets in patients after allo-HSCT. (A) Represent
Inhibition rate of MDSC subsets on lymphocyte proliferation. (C) Representative ﬁgu
cells. (E) Representative ﬁgure of percentages of CD4þCD25þFoxp3þ Tregs (gated on C
results represent 1 of 2 patient experiments. *P < .05, **P < .01, ***P < .001.post-transplant growth factor administration may be
affecting both the number and function of MDSC in the post-
transplant milieu and may be an explanation for differences
in GVHD with hematopoietic growth factor usage. Increasing
MDSC activity selectively post-transplantdthrough cytokine
administration or cellular infusiondmay be a tactic for pre-
venting/treating GVHD while preserving the GVL effect.
Taken together, we demonstrate that both M-MDSC and
G-MDSC subsets recover early after HSCT, well before adap-
tive immune CD3þ T and CD19þ B cells; G-MDSCs/M-MDSCs
recovery positively correlated with other immune cells at
different times after HSCT; and G-MDSCs in patients at the
preconditioning time point and the ratio of G-MDSCs at days
27 to 29 over baseline may predict the development of acute
GVHD. These early post-HSCT MDSC subsets are functional;
they suppress T cell proliferation and Th1 differentiation
while promoting the development Tregs. This suggests that
MDSCs may play an important role in the pathophysiology of
GVHD and GVL and potentially are a target for therapeutic
manipulation.
ACKNOWLEDGMENTS
The authors thank Ms. Erin Richardson and Dr. Kristjan
Paulson for providing clinical outcome data.
Financial disclosure: This study was supported by Cancer-
Care Manitoba Foundation (Grant #763009109 to D.A.W. and
Q.G.) and CBMTG Young Investigator Research Grant (to Q.G.).
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
Authorship statement: Q.G., G.D.E.C, and D.A.W. conceived
and designed the project. Q.G., A.B., K.A., O.S., M.T., A.G., and
B.Y. performed the experiments. Z.P. provided expertise in
assay design. Q.G., P.L. and D.A.W. analyzed the data. Q.G. and
D.A.W. wrote the manuscript. A.B., K.A., O.S., M.T., A.G., B.Y., Z.
P., and G.D.E.C. critically reviewed the manuscript. Q.G. and
D.A.W. are co-corresponding authors.
REFERENCES
1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regula-
tors of the immune system. Nat Rev Immunol. 2009;9:162-174.
2. Bronte V. Myeloid-derived suppressor cells in inﬂammation: uncov-
ering cell subsets with enhanced immunosuppressive functions. Eur J
Immunol. 2009;39:2670-2672.ative ﬁgures of CD4þ T lymphocyte proliferation (gated on CD4þ T cells). (B)
re of percentages of CD4þIFN-gþ Th1 cells. (D) Percentage of CD4þIFN-gþ Th1
D4þ T cells). (F) Percentages of CD4þCD25þFoxp3þ Tregs in the coculture. The
Q. Guan et al. / Biol Blood Marrow Transplant 21 (2015) 1205e121412143. Cripps JG, Gorham JD. MDSC in autoimmunity. Int Immunopharmacol.
2011;11:789-793.
4. Chou H, Hsieh C, Yang H, et al. Hepatic stellate cells regulate immune
response by way of induction of myeloid suppressor cells. Hepatology.
2011;53:1007-1019.
5. Ochando JC, Chen SH. Myeloid-derived suppressor cells in trans-
plantation and cancer. Immunol Res. 2012;54:275-285.
6. Deshane J, Zmijewski JW, Luther R, et al. Free radical-producing
myeloid-derived regulatory cells: potent activators and suppressors
of lung inﬂammation and airway hyperresponsiveness. Mucosal
Immunol. 2011;4:503-518.
7. Guan Q, Moreno S, Qing G, et al. The role and potential therapeutic
application of myeloid-derived suppressor cells in TNBS-induced coli-
tis. J Leukoc Biol. 2013;94:803-811.
8. Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune
suppression depend on the C/EBPbeta transcription factor. Immunity.
2010;32:790-802.
9. Condamine T, Gabrilovich DI. Molecular mechanisms regulating
myeloid-derived suppressor cell differentiation and function. Trends
Immunol. 2011;32:19-25.
10. Mougiakakos D, Jitschin R, von Bahr L, et al. Immunosuppressive
CD14þHLA-DRlow/neg IDOþ myeloid cells in patients following allo-
geneic hematopoietic stem cell transplantation. Leukemia. 2013;27:
377-388.
11. Vendramin A, Gimondi S, Bermema A, et al. Graft monocytic
myeloid-derived suppressor cell content predicts the risk of acute
graft-versus-host disease after allogeneic transplantation of gran-
ulocyte colony-stimulating factor-mobilized peripheral blood stem
cells. Biol Blood Marrow Transplant. 2014;20:2049-2055.
12. Luyckx A, Schouppe E, Rutgeerts O, et al. G-CSF stem cell mobilization
in human donors induces polymorphonuclear and mononuclear
myeloid-derived suppressor cells. Clin Immunol. 2012;143:83-87.
13. Brudecki L, Ferguson DA, McCall CE, El Gazzar M. Myeloid-derived
suppressor cells evolve during sepsis and can enhance or attenuate the
systemic inﬂammatory response. Infect Immun. 2012;80:2026-2034.
14. Wang D, Yu Y, Haarberg K, et al. Dynamic change and impact of
myeloid-derived suppressor cells in allogeneic bone marrow trans-
plantation in mice. Biol Blood Marrow Transplant. 2013;19:692-702.
15. Highﬁll SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived
suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via
an arginase-1-dependent mechanism that is up-regulated by inter-
leukin-13. Blood. 2010;116:5738-5747.16. Zhou Z, French DL, Ma G, et al. Development and function of myeloid-
derived suppressor cells generated from mouse embryonic and he-
matopoietic stem cells. Stem Cells. 2010;28:620-632.
17. Rieber N, Wecker I, Neri D, et al. Extracorporeal photopheresis in-
creases neutrophilic myeloid-derived suppressor cells in patients with
GvHD. Bone Marrow Transplant. 2014;49:545-552.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference
on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
19. Laborde RR, Lin Y, Gustafson MP, et al. Cancer vaccines in the world of
immune suppressive monocytes (CD14(þ)HLA-DR(lo/neg) cells): the
gateway to improved responses. Front Immunol. 2014;5:147.
20. Dumitru CA, Moses K, Trellakis S, et al. Neutrophils and granulocytic
myeloid-derived suppressor cells: immunophenotyping, cell biology
and clinical relevance in human oncology. Cancer Immunol Immun-
other. 2012;61:1155-1167.
21. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in
human diseases. Int Immunopharmacol. 2011;11:802-807.
22. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after
allogeneic marrow transplantation compared with blood stem cell
transplantation. Blood. 2001;97:3380-3389.
23. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system
after hematopoietic stem cell transplantation in humans. Semin
Immunopathol. 2008;30:425-437.
24. Juvet SC, Zhang L. Double negative regulatory T cells in transplantation
and autoimmunity: recent progress and future directions. J Mol Cell
Biol. 2012;4:48-58.
25. Lv M, Zhao XS, Hu Y, et al. Monocytic and promyelocytic myeloid-
derived suppressor cells may contribute to G-CSF-induced immune
tolerance in haplo-identical allogeneic hematopoietic stem cell trans-
plantation. Am J Hematol. 2015;90:E9-E16.
26. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-
induced myeloid-derived suppressor cells from normal human pe-
ripheral blood mononuclear cells. J Immunol. 2010;185:2273-2284.
27. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease
biology and therapy. Nat Rev Immunol. 2012;12:443-458.
28. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine levels and
acute graft-versus-host disease after HLA-identical hematopoietic stem
cell transplantation. Exp Hematol. 2003;31:1044-1050.
29. Min CK, Lee WY, Min DJ, et al. The kinetics of circulating cytokines
including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic he-
matopoietic stem cell transplantation. Bone Marrow Transplant. 2001;
28:935-940.
